What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated ...

10x Genomics has marked a new phase in its remarkable expansion by opening a modern office building that has just sprouted in Pleasanton.

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other genomics ...

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for.

10x Genomics delivered a solid Q3 quarter with revenue reaching $154M, growing 17% YoY. Learn why we recommend a Buy rating for TXG stock.

10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. Find out why TXG is poised for sustained growth.

10x Genomics (NASDAQ: TXG), a biotechnology company that designs and manufactures gene sequencing technology, was listed following its IPO in September. While the stock saw some volatility post ...

Genomics startup Parse Biosciences lost its bid to dismiss a patent-infringement lawsuit brought by rival 10x Genomics and Stanford University on Thursday, when a Delaware federal court denied ...

10x Genomics has crafted plans for a major expansion of its Pleasanton operations through the purchase of a big property that it will develop as a modern campus.

Life-sciences technology startup 10x Genomics Inc. said its initial public offering was priced above the high end of the expected range, giving it a valuation topping $3.6 billion.